ProMetic Life Sciences Inc. ABOUT PROMETIC LIFE SCIENCES INC.
ProMetic Life Sciences Inc. (www.prometic.com) is a long established biopharmaceutical company with globally recognized expertise in bioseparation, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Europe, Russia, Australia and Asia.

Industries:
Medical/Pharmaceuticals | Biotechnology
Contact Information:
Frederic Dumais
Senior Director, Communications and Investor Relations
ProMetic Life Sciences Inc.
f.dumais@prometic.com
+1.450.781.0115

Latest

May 22, 2019, 08:30 ET Prometic presents new PBI-4050 and Ryplazim™ (plasminogen) data on lung fibrosis at the 2019 ATS Conference

LAVAL, QC and CAMBRIDGE, United Kingdom, May 22, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced the presentation of three scientific posters on...


May 15, 2019, 15:08 ET Prometic announces terms of equity rights offering

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ LAVAL, QC, May 15, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the ...


May 08, 2019, 19:46 ET Prometic reports its 2019 first quarter financial results

Completion of recapitalization transactions and $75 million in gross proceeds secured from equity offering New CEO, Board appointees and management structure to strengthen Corporation's leadership $8....


May 08, 2019, 18:31 ET Prometic strengthens its leadership with a new management structure and the appointment of three new directors

LAVAL, QC and CAMBRIDGE, United Kingdom, May 8, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or "Corporation") is pleased to announce today a new management...


Apr 23, 2019, 12:33 ET Prometic Completes Refinancing Transactions Including C$75 Million (approximately US$56 Million) in Gross Proceeds from New Equity Financing

Stefan Clulow appointed as Chair of the Board Kenneth Galbraith appointed as Chief Executive Officer /NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ LAVAL, QC, ...


Apr 15, 2019, 07:00 ET Prometic Announces Refinancing Transactions

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ LAVAL, QC, April 15, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or...


Apr 01, 2019, 18:20 ET Prometic reports fourth quarter and 2018 year-end financial results

Total revenues for 2018 of $47.4 million compared to $39.1 million in 2017 Significant increase in bioseparation 2018 revenues to $22.7 million, a 35% increase over 2017 Net loss of $ 237.9 million...


Mar 26, 2019, 12:32 ET Prometic to Report its Fourth Quarter and 2018 Year-End Financial Results and Hold Conference Call / Webcast

LAVAL, QC, March 26, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it will report its financial results for the...


Mar 25, 2019, 07:00 ET Prometic secures additional USD $5 million (CAD $6.7 million) tranche from structured Alpha LP, an affiliate of Thomvest Asset Management Inc., under

LAVAL, QC, March 25, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has secured an additional USD $5 million (CAD...


Feb 25, 2019, 07:00 ET Prometic secures additional USD $10 million (CAD $13.2 million) tranche from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.,

LAVAL, QC, Feb. 25, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has secured an additional USD $10 million (CAD...


Feb 14, 2019, 07:00 ET Prometic retains investment bank for strategic transactions

LAVAL, QC, Feb. 14, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI), (OTCQX: PFSCF) ("Prometic" or the "Corporation") today announced that it has engaged Lazard to review and execute key...


Dec 19, 2018, 07:30 ET Prof. Simon Best Appointed Interim CEO of Prometic Life Sciences

LAVAL, QC, Dec. 19, 2018 /CNW/ - The Board of Directors of Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has named Prof. Simon Best...


Dec 05, 2018, 09:34 ET Prometic to Initiate PBI-4050 Pivotal Phase 3 Clinical Trial in Alström Syndrome

Clinical-regulatory pathway defined following recent meetings with regulatory authorities Pivotal Phase 3 clinical trial design finalized to support regulatory submissions in the U.S. and Europe...


Nov 28, 2018, 07:00 ET Prometic Provides Corporate Update

LAVAL, QC, Nov 28, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") has previously announced a series of initiatives to lengthen its cash...


Nov 14, 2018, 20:39 ET Prometic Reports Third Quarter 2018 Financial Results and Highlights

Extension of maturity dates of Line of Credit and OID Loans to September 2024 Implementation of cost control measures to significantly reduce operational burn and extend cash runway Substantial...


Nov 14, 2018, 12:51 ET Prometic Closes its Extension of Debt Maturities to 2024

Maturity Dates of the Line of Credit and Long-Term (OID) Loans extended to September 2024 One of a number of measures underway to extend cash runway Significant reduction in R&D costs of up to $30...


Nov 12, 2018, 17:34 ET Prometic to Report its Third Quarter 2018 Financial Results and Hold Conference Call / Webcast

LAVAL, QC, Nov. 12, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will report its financial results for the third quarter ended...


Oct 29, 2018, 07:00 ET Prometic Announces Extension of Debt Maturities to 2024

Maturity Date of Line of Credit to be Extended from November 2019 to September 2024 Maturity Date of Long-Term (OID) Loans to be Extended from July 2022 to September 2024 LAVAL, QC, Oct. 29, 2018...


Oct 16, 2018, 06:30 ET Prometic announces positive feedback from FDA Type-C meeting on Ryplazim™ (plasminogen) BLA

Implementation plan for additional analytical assays and in-process controls confirmed Company finalizing process performance qualification (PPQ) protocol in order to proceed with the manufacturing...


Sep 05, 2018, 12:23 ET Prometic to host Key Opinion Leader meeting on PBI-4050, a novel treatment for Alström Syndrome and promising therapeutic for non alcoholic

LAVAL, QC, Sept. 5, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") reported today that it will host a Key Opinion Leader meeting on PBI-4050, a novel treatment ...


Aug 14, 2018, 18:07 ET Prometic Reports Second Quarter 2018 Financial Results and Highlights

Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen) Submitted plan to FDA regarding filing of...


Aug 10, 2018, 07:15 ET Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in Journal of Pharmacology and Experimental Therapeutics

PBI-4050 reduces the activation of hepatic stellate cells, the major cells involved in liver fibrosis PBI-4050 decreases liver fibrosis through modulation of the LKB1-AMPK-mTOR pathway AMPK acts as...


Aug 07, 2018, 14:21 ET Prometic to report its second quarter 2018 financial results and hold conference call / webcast

LAVAL, QC, Aug. 7, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will report its financial results for the second quarter ended June...


Aug 07, 2018, 07:00 ET Prometic receives Rare Pediatric Disease Designation from U.S. FDA for small molecule drug candidate, PBI-4050

Rare Pediatric Disease Designation granted for the treatment of patients with Alström syndrome Third Rare Pediatric Disease Designation obtained by Prometic LAVAL, QC, Aug. 7, 2018 /CNW Telbec/ -...


Jun 22, 2018, 12:38 ET Prometic conference call to present progress report on AGM corporate action plan

LAVAL, QC, June 22, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will hold a conference call on Wednesday June 27, 2018 to report on...